Zentalis (ZNTL) CMO Ingmar Bruns Buys 9,727 Shares via ESPP

What Happened
Ingmar Bruns, Chief Medical Officer of Zentalis Pharmaceuticals (ZNTL), acquired 9,727 shares of the company’s common stock on September 30, 2026. The shares were purchased at $2.18 per share for a total of $21,205 under the company’s Employee Stock Purchase Plan (ESPP). This is an acquisition (award/purchase) transaction rather than a sale.

Key Details

• Transaction date and price: 2026-09-30, 9,727 shares at $2.18 each (total $21,205).
• Transaction type: Acquisition under the 2020 ESPP (reported as code A).
• Footnotes:
  • F1 — Reporting is voluntary; the purchase is under the ESPP purchase period April 1, 2026 through September 30, 2026 and is exempt under Rule 16b-3(c).
  • F2 — Shares were purchased using a lookback/discount feature: based on 85% of the closing price on April 1, 2026.
• Shares owned after transaction: not disclosed in this Form 4 filing.
• Filing timeliness: Form 4 was filed on 2026-10-01 for a 2026-09-30 transaction; this appears to be within the standard reporting window (no late filing indicated).

Context
This was a standard ESPP purchase — a common employee benefit that lets insiders buy company stock at a discount (here, 85% of the April 1 closing price). Such purchases are factual signals of insider buying but are often part of routine compensation plans rather than discretionary market timing. The transaction is exempt from certain short-swing profit rules under Rule 16b-3(c) because it was made under the company ESPP.